The combination of protease inhibitors (PIs) with HAART -- a mainstay of treatment for patients with HIV infection -- is commonly associated with hypercholesterolaemia and hypertriglyceridaemia. The use of NVP, however, has provided a therapy with limited adverse effects on patients' lipid profiles, noted principal investigator Cristina Hidalgo, MD, Infectious Diseases Division, Fundación Jiménez Diaz, Madrid, Spain, speaking here on April 11.